Zhengye Biotechnology Holding (ZYBT) Prepaid Assets (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Prepaid Assets of $3.6 million for Q4 2025, up 889.89% year-on-year from $365580.5 in Q4 2024, and up 0.78% on a QoQ basis from $3.6 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Prepaid Assets (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Prepaid Assets for 2 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- Quarterly Prepaid Assets rose 889.89% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 889.89% YoY) and the FY2025 annual result came in at $3.7 million, up 903.88% from the prior year.
- Prepaid Assets climbed to $3.6 million in Q4 2025 per ZYBT's latest filing, from $3.6 million in the prior quarter.
- Over the last five years, Prepaid Assets for ZYBT reached as high as $3.6 million in Q4 2025 and fell as low as $365580.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Zhengye Biotechnology Holding | 85.23 Mn | 85.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.62 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Dec 31, 2024 | 365,580.48 |